{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:08:13Z","timestamp":1769911693599,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir\/pibrentasvir (GLE\/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in clinical trials, yet who will be crucial for achieving hepatitis C virus (HCV) elimination. The DHC-R is an ongoing, non-interventional, multicenter, prospective, observational cohort study on patients treated for chronic HCV infection in Germany. The data cutoff was 17 January 2021. The primary effectiveness endpoint was sustained virologic response at post-treatment Week 12 (SVR12). Safety outcomes were assessed in all patients receiving GLE\/PIB. PROs were assessed using the SF-36 survey. Of 2354 patients, 1964 had valid SVR12 data (intention-to-treat analysis). Of these, 1905 (97.0%) achieved SVR12 with rates similar across the comorbidities analyzed, except for people who actively use drugs (PWUD (active)) (86.4%). Excluding those who discontinued treatment and did not achieve SVR12, or were reinfected with HCV, the rate was 99.3%, with similar results regardless of comorbidity. PWUD (active) and those with psychiatric disorders had the most meaningful improvements in PROs. Adverse events (AEs) occurred in 631\/2354 patients (26.8%), and serious AEs in 44 patients (1.9%). GLE\/PIB was highly effective and well tolerated in this real-world study of patient groups key to HCV elimination.<\/jats:p>","DOI":"10.3390\/v14071541","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T01:57:11Z","timestamp":1657850231000},"page":"1541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir\/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)"],"prefix":"10.3390","volume":"14","author":[{"given":"Markus","family":"Cornberg","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Hannover Medizinische Hochschule, 30625 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stoehr","sequence":"additional","affiliation":[{"name":"IFI Medizin GmbH, 20099 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Naumann","sequence":"additional","affiliation":[{"name":"UBN-Praxis, 14059 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Teuber","sequence":"additional","affiliation":[{"name":"Practice PD Dr. med. G. Teuber, 60594 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[{"name":"Infektiologikum, 60596 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hj\u00f6rdis","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Leberzentrum am Checkpoint, 10961 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-2323","authenticated-orcid":false,"given":"Dennis","family":"Hidde","sequence":"additional","affiliation":[{"name":"AbbVie Germany GmbH & Co., KG, 65189 Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lohmann","sequence":"additional","affiliation":[{"name":"AbbVie Germany GmbH & Co., KG, 65189 Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-2989","authenticated-orcid":false,"given":"Karl-Georg","family":"Simon","sequence":"additional","affiliation":[{"name":"MVZ Dres Eisenbach\/Simon\/ Schwarz\/GbR, 51375 Leverkusen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, May 03). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_2","unstructured":"Polaris Observatory (2021, May 11). German HCV Infections. Available online: https:\/\/cdafound.org\/dashboard\/polaris\/dashboard.html."},{"key":"ref_3","unstructured":"World Health Organization (2022, May 03). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/246177."},{"key":"ref_4","unstructured":"World Health Organization (2022, May 03). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241550345."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_6","unstructured":"American Association for the Study of Liver Diseases (2021, June 07). AASLD HCV Guidelines. Available online: https:\/\/www.hcvguidelines.org."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: An updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12954-018-0248-4","article-title":"Beyond cure: Patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia","volume":"15","author":"Madden","year":"2018","journal-title":"Harm Reduct. J."},{"key":"ref_9","unstructured":"AbbVie (2020, March 20). Maviret (Glecaprevir\/Pibrentasvir) Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): An open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and Pharmacokinetics of Glecaprevir\/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: A review of the available evidence","volume":"49","author":"Hellard","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J. Community Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.idc.2018.02.001","article-title":"Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice","volume":"32","author":"Norton","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_20","first-page":"27","article-title":"4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)","volume":"57","author":"Huppe","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: Data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 Health Survey Update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","article-title":"Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn\u2019s disease","volume":"29","author":"Coteur","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-11-82","article-title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: Results from a phase IIb randomized, controlled study","volume":"11","author":"Strand","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2017.11.009","article-title":"Real-world effectiveness of 8-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C","volume":"68","author":"Buggisch","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/jvh.13586","article-title":"The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R)","volume":"28","author":"Huppe","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ofaa055","DOI":"10.1093\/ofid\/ofaa055","article-title":"Real-world Effectiveness of Sofosbuvir\/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study","volume":"7","author":"Wilton","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Edmunds, B.L., Miller, E.R., and Tsourtos, G. (2019). The distribution and socioeconomic burden of Hepatitis C virus in South Australia: A cross-sectional study 2010-2016. BMC Public Health, 19.","DOI":"10.1186\/s12889-019-6847-5"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Greenaway, C., Makarenko, I., Chakra, C.N.A., Alabdulkarim, B., Christensen, R., Palayew, A., Tran, A., Staub, L., Pareek, M., and Meerpohl, J.J. (2018). The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU\/EEA: A Systematic Review. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15092013"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","article-title":"Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases\u2014United States, 2009\u20132018","volume":"69","author":"Ryerson","year":"2020","journal-title":"MMWR Morb. Morb. Wkly. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Schmidbauer, C., Schubert, R., Schutz, A., Schwanke, C., Luhn, J., Gutic, E., Pirker, R., Lang, T., Reiberger, T., and Haltmayer, H. (2020). Directly observed therapy for HCV with glecaprevir\/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229239"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.14745","article-title":"Feasibility and efficacy of 8 week Glecaprevir\/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study","volume":"41","author":"Fiore","year":"2021","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"ofaa317","DOI":"10.1093\/ofid\/ofaa317","article-title":"Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study","volume":"7","author":"Schulte","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Smith-Palmer, J., Cerri, K., and Valentine, W. (2015). Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0748-8"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/7\/1541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:28Z","timestamp":1760140228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/7\/1541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["v14071541"],"URL":"https:\/\/doi.org\/10.3390\/v14071541","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}